Robotic partial nephrectomy after pazopanib treatment in a solitary kidney with segmental vein thrombosis. uri icon

Overview

abstract

  • OBJECTIVE: To demonstrate our surgical technique of robotic partial nephrectomy (RPN) in a patient with a solitary kidney who received neoadjuvant Pazopanib, highlighting the multidisciplinary approach. MATERIALS AND METHODS: In our video, we present the case of 77-year-old male, Caucasian with 6.6cm left renal neoplasm in a solitary kidney. An initial percutaneous biopsy from the mass revealed clear cell RCC ISUP 2. After multidisciplinary tumor board meeting, Pazopanib (800mg once daily) was administered for 8 weeks with repeat imaging at completion of therapy. Post-TKI image study was compared with the pre-TKI CT using the Morphology, Attenuation, Size, and Structure criteria showing a favorable response to the treatment. Thereafter, a RPN was planned3. Perioperative surgical outcomes are presented. RESULTS: Operative time was 224 minutes with a cold ischemia time of 53 minutes. Estimated blood loss was 800ml and the length of hospital stay was 4 days. Pathology demonstrated a specimen of 7.6cm with a tumor size of 6.5cm consistent with clear cell renal carcinoma ISUP 3 with a TNM staging pT1b Nx. Postoperative GFR was maintained at 24 ml / min compared to the preoperative value of 33ml / min. CONCLUSIONS: A multidisciplinary approach is effective for patients in whom nephron preservation is critical, providing na opportunity to select those that may benefi t from TKI therapy. Pazopanib may allow for PN in a highly selective subgroup of patients who would otherwise require radical nephrectomy. Prospective data will be necessary before this strategy can be disseminated into clinical practice. Available at: http://www.intbrazjurol.com.br/video-section/20180240_Garisto_et_al.

publication date

  • January 1, 2019

Research

keywords

  • Nephrectomy
  • Pyrimidines
  • Receptors, Vascular Endothelial Growth Factor
  • Robotic Surgical Procedures
  • Solitary Kidney
  • Sulfonamides
  • Venous Thrombosis

Identity

PubMed Central ID

  • PMC6837620

Scopus Document Identifier

  • 85071345836

Digital Object Identifier (DOI)

  • 10.1590/S1677-5538.IBJU.2018.0240

PubMed ID

  • 30901174

Additional Document Info

volume

  • 45

issue

  • 4